Houlihan Financial Resource Group’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$260K Hold
1,700
0.1% 101
2025
Q4
$248K Buy
+1,700
New +$223K 0.09% 103
2025
Q2
Sell
-1,850
Closed -$206K 108
2025
Q1
$206K Buy
+1,850
New +$197K 0.09% 100
2024
Q4
Sell
-2,200
Closed -$253K 104
2024
Q3
$253K Hold
2,200
0.1% 98
2024
Q2
$234K Hold
2,200
0.16% 57
2024
Q1
$213K Hold
2,200
0.1% 98
2023
Q4
$222K Hold
2,200
0.11% 96
2023
Q3
$214K Sell
2,200
-76,250
-97% -$7.74M 0.11% 92
2023
Q2
$7.85M Buy
78,450
+76,250
+3,466% +$7.63M 0.24% 41
2023
Q1
$202K Buy
+2,200
New +$192K 0.11% 88
2020
Q3
$299K Buy
+3,475
New +$301K 0.17% 80
2020
Q1
$287K Sell
3,475
-50
-1% -$4.46K 0.25% 68
2019
Q4
$334K Buy
+3,525
New +$316K 0.22% 76

Other funds holding NVS

Houlihan Financial Resource Group's NVS Position: Q1 2026 in Review

Houlihan Financial Resource Group held its Novartis (NVS) position steady in Q1 2026 at 1,700 shares worth $260K. The position accounts for 0.1% of the portfolio, ranked #101.

Houlihan Financial Resource Group first reported a position in NVS in Q4 2019 and has held it in 13 quarters since. The position peaked at $7.85M in Q2 2023. 1,592 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • Houlihan Financial Resource Group held 1,700 shares of Novartis worth $260K as of Q1 2026.
  • Houlihan Financial Resource Group left its Novartis share count unchanged in Q1 2026.
  • Novartis made up 0.1% of Houlihan Financial Resource Group's portfolio in Q1 2026, its #101 holding.
  • Houlihan Financial Resource Group first reported a position in Novartis in Q4 2019 and has held it in 13 quarters since.
  • Houlihan Financial Resource Group's Novartis position peaked at $7.85M in Q2 2023.
  • 1,592 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Houlihan Financial Resource Group's 13F filing for Q1 2026, filed 29 Apr 2026.